Clinical trials: Molecular Mechanisms of Pharmacological Action
Schizophrenia, Psychotic Disorders
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
This is a randomized, single-dose, open-label, parallel-group study. Patients will undergo the screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05321602
- Testing
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid
- Where
- 9 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia, Psychotic Disorders
Relative Bioavailability of LY03010 Compared to Listed Drug
This is a randomized, multiple-dose, open-label, parallel-group study. Subjects will undergo screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum
- Trial name
- NCT04922593
- Testing
- LY03010; paliperidone palmitate, INVEGA SUSTENNA
- Where
- 9 sites in United States
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Molecular Mechanisms of Pharmacological Action, Depression
Effects of Seven Day Prucalopride Administration in Healthy Volunteers
This study will investigate whether seven days administration of the serotonin receptor subtype 4 (5-HT4) partial agonist prucalopride has effects on emotional processing and neural activity in healthy volunteers, compared to…
- Conditions
- Molecular Mechanisms of Pharmacological Action, Depression, Depressive Disorder, Mood Disorders
- Trial name
- NCT03572790
- Testing
- Prucalopride
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Pharmacokinetics, Molecular Mechanisms of Pharmacological Action
Pharmacometabolomics of Andrographis Paniculata And Metformin In Healthy Volunteers Under Fasting Condition
This study is a phase 1, open label, randomized, three-way crossover, single dose, oral- administration of Andrographis paniculata and Metformin in healthy volunteers under fasting condition.
- Trial name
- NCT04161404
- Testing
- Brand name: Andrographis paniculata (Shine Hempedu Bumi) 1000mg capsules, Brand name: Andrographis paniculata (Shine Hempedu Bumi) 2000mg, Metformin (Glucophage) 1000mg
- Where
- Malaysia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Malaya
Molecular Mechanisms of Pharmacological Action, Depression
Citalopram and Self Emotional Processing
This study is investigating the effect of an acute dose of citalopram on emotional processing about the self. Using a parallel-group double-blind design, participants will be randomised to receive either an acute dose of…
- Conditions
- Molecular Mechanisms of Pharmacological Action, Depression, Depressive Disorder, Mental Disorder
- Trial name
- NCT04169230
- Testing
- Citalopram
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Molecular Mechanisms of Pharmacological Action, Depression
Effects of Acute Prucalopride Administration in Healthy Volunteers
This study will investigate whether administration of a single dose of the serotonin receptor subtype 4 (5-HT4) partial agonist prucalopride has effects on emotional processing and non-emotional cognition in healthy volunteers…
- Conditions
- Molecular Mechanisms of Pharmacological Action, Depression, Depressive Disorder, Mood Disorders
- Trial name
- NCT03863366
- Testing
- Prucalopride
- Where
- United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Molecular Mechanisms of Pharmacological Action
A Study to Investigate the Mass Balance of BTD-001
This is a single-centre, open-label, non-randomised, single oral dose study in healthy male subjects to assess the mass balance recovery of carbon-14 (14C)-BTD-001.
- Trial name
- HV103 (NCT03107013)
- Testing
- [14C]-BTD-001
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Balance Therapeutics